1.05
-0.03(-2.78%)
Currency In USD
| Previous Close | 1.08 |
| Open | 1.1 |
| Day High | 1.13 |
| Day Low | 1.05 |
| 52-Week High | 2.26 |
| 52-Week Low | 0.4 |
| Volume | 410,909 |
| Average Volume | 927,667 |
| Market Cap | 56.23M |
| PE | -0.49 |
| EPS | -2.16 |
| Moving Average 50 Days | 0.78 |
| Moving Average 200 Days | 0.92 |
| Change | -0.03 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $35 as of September 17, 2025 at a share price of $1.05. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 3 years ago, it would be worth $95.28 as of September 17, 2025 at a share price of $1.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
GlobeNewswire Inc.
Sep 12, 2025 12:30 PM GMT
Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Offi
ALX Oncology to Participate in Upcoming Investor Conferences in September
GlobeNewswire Inc.
Aug 29, 2025 4:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
GlobeNewswire Inc.
Aug 19, 2025 12:00 PM GMT
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 bu